Journal of Generic Medicines

FIGURES AND TABLES

FROM:

Patent expiries in the US statin market: Generics to slash market size by 80 per cent over the next ten years

Duncan Emerton

BACK TO ARTICLE
Figure 1 - Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, please contact help@nature.com or the author

Figure 1.

Likely scenarios for switching from Zocor to generic simvastatin, and the effect of generic atorvastatin from 2011 on generic simvastatin sales
Source: Datamonitor

Full figure and legend (132K)
Figure 2 - Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, please contact help@nature.com or the author

Figure 2.

Between 2006 and 2011, the value of the branded US statin monotherapy market is expected to fall by US$8bn (50 per cent) due to generic incursion on branded statin revenues
Source: Datamonitor forecasts; patent data obtained from Dolphin, Q2 2006, © Thomson Scientific; FDA Orange Book; MedTRACK, © Datamonitor plc; all accessed during July 2006

Full figure and legend (95K)
Table 1 - The US statin monotherapy[ast] market, 2005 - Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, please contact help@nature.com or the author

Table 1 - The US statin monotherapy* market, 2005.

Full table
Table 2 - Patent position for each of the statins in the US - Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, please contact help@nature.com or the author

Table 2 - Patent position for each of the statins in the US.

Full table
BACK TO ARTICLE